NETRIS Pharma focuses its activities on Dependence Receptors in oncology

and the therapeutic potential of interfering with the ligand-receptor interaction

The therapeutic strategy is thus to generate candidate drugs blocking the interaction between the ligand and its Dependence Receptor, to treat patient suffering from cancer displaying production of the ligand to restore cancer cell death and consequently induce tumor regression. This strategy falls within the framework of targeted therapies. Biomarkers are being investigated to identify patients who may benefit from this approach.

The relevance of the strategy has been validated through numerous preclinical “proof of concept” experiments. Such validation has been further enhanced by the positive outcome of the phase 1 clinical trial of Netris Pharma in solid tumors.